Rhythm Pharmaceuticals (RYTM) Cost of Revenue (2021 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Cost of Revenue of $7.2 million for Q1 2026, up 96.19% year-over-year from $3.6 million in Q1 2025, and up 49.04% quarter-over-quarter from $4.8 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Cost of Revenue (2021 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Cost of Revenue for 6 consecutive years, with $7.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cost of Revenue rose 96.19% year-over-year to $7.2 million; the TTM figure through Mar 2026 stood at $23.0 million (up 61.86% YoY), while the FY2025 annual figure was $19.5 million, up 45.81% from the prior year.
- Cost of Revenue improved to $7.2 million in Q1 2026 per RYTM's latest filing, from $4.8 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $7.2 million in Q1 2026 and bottomed at $230000.0 in Q1 2022.
- Historically, Cost of Revenue has averaged $3.0 million across 5 years, with a median of $2.9 million in 2024.
- Annual changes were most pronounced in 2022 — Cost of Revenue jumped 5650.0% — and 2024, when it advanced 17.14%.
- Rhythm Pharmaceuticals' Cost of Revenue stood at $1.0 million in 2022, then soared by 214.49% to $3.2 million in 2023, then grew by 17.14% to $3.8 million in 2024, then increased by 26.8% to $4.8 million in 2025, then soared by 49.04% to $7.2 million in 2026.
- Business Quant data shows RYTM's Cost of Revenue at $7.2 million in Q1 2026, $4.8 million in Q4 2025, and $5.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | 8.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.93 Mn |
| Jun 30, 2026 | 8.93 Mn |
| Mar 31, 2026 | 7.16 Mn |
| Mar 31, 2026 | 7.16 Mn |
| Dec 31, 2025 | 4.80 Mn |
| Dec 31, 2025 | 4.80 Mn |
| Sep 30, 2025 | 5.50 Mn |
| Sep 30, 2025 | 5.50 Mn |
| Jun 30, 2025 | 5.54 Mn |
| Jun 30, 2025 | 5.54 Mn |
| Mar 31, 2025 | 3.65 Mn |
| Mar 31, 2025 | 3.65 Mn |
| Dec 31, 2024 | 3.79 Mn |
| Dec 31, 2024 | 3.79 Mn |
| Sep 30, 2024 | 3.83 Mn |
| Sep 30, 2024 | 3.83 Mn |
| Jun 30, 2024 | 2.95 Mn |
| Jun 30, 2024 | 2.95 Mn |
| Mar 31, 2024 | 2.81 Mn |
| Mar 31, 2024 | 2.81 Mn |